Achieve Life Sciences (ACHV) vs DBV Technologies S.A. (DBVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 51.9% versus a loss of 46.6%. Over five years, DBVT leads with a -18.0% price change compared with -20.4% for ACHV. Achieve Life Sciences is the larger company by market cap ($657.8 million vs $568.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | DBVT |
|---|---|---|
| Share price | $6.38 | $9.05 |
| Market cap | $657.79M | $568.78M |
| 1-day change | -8.46% | -0.66% |
| YTD return | +28.37% | -52.79% |
| 1-year return | +51.90% | -46.61% |
| 5-year return | -20.45% | -18.03% |
| EPS (TTM) | $-1.69 | $-3.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $5.64M |
| Revenue growth (YoY) | — | +35.77% |
| Net income (latest FY) | $-54.65M | $-146.95M |
| Operating margin | — | -2609.23% |
| Net margin | — | -2607.29% |
| 52-week high | $8.64 | $26.19 |
| 52-week low | $2.62 | $8.63 |
| Distance from 52-week high | -26.16% | -65.44% |
| Analyst consensus | none | none |
| Avg. price target upside | +121.79% | +328.07% |
| Average volume | 1.41M | 350.73K |
| Shares outstanding | 103.10M | 62.85M |
| Employees | 28 | 170 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed DBVT by 98.5 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Healthcare · Biotechnology · 28 employees
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Healthcare · Biotechnology · 170 employees
ACHV vs DBVT FAQ
Which is bigger, Achieve Life Sciences or DBV Technologies S.A.?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $657.79M compared with $568.78M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, ACHV or DBVT?
ACHV returned +51.90% over the past 12 months, compared with -46.61% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and DBV Technologies S.A. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.